Lucid Diagnostics Inc. (LUCD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
One Grand Central Place
New York City, NY 10165
United States of America (the)
Phone
212 949 4319
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
72
First IPO Date
October 14, 2021
| Name | Title | Pay | Year Born |
| Lishan Aklog | Chairman & Chief Executive Officer | 450,000 | 1966 |
| Amitabh Chak | Co-founder & Strategic Advisor | 14,535 | N/A |
| Joseph Willis | Co-founder & Strategic Advisor | 14,535 | N/A |
| Sanford D. Markowitz | Co-founder & Strategic Advisor | 14,535 | N/A |
| Helen Moinova | Co-founder & Strategic Advisor | 14,535 | N/A |
| Dennis McGrath | Chief Financial Officer | 303,750 | 1957 |
| Michael Adam Gordon | General Counsel & Secretary | 312,500 | 1975 |
| Shaun O'Neill | President & Chief Operating Officer | 375,000 | 1982 |
| Brian J. deGuzman | Chief Technology & Compliance Officer | 0 | 1965 |
| Deepika A. Lakhani | Senior Vice President, Chief Regulatory & Quality Officer | 0 | N/A |
| Danielle W. Scelfo | Senior Vice President of Market Access & Government Affairs | 0 | N/A |
| Suman Verma | Senior VP & Chief Scientific Officer | 0 | N/A |
| Matthew Riley | Director of Investor Relations | 0 | N/A |
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.